Skip to main content
JYNT
NASDAQ Real Estate & Construction

JOINT Corp Beats Q2 Revenue, Swings to H1 Profit as Refranchising Gains Traction

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.15
Mkt Cap
$117.179M
52W Low
$7.5
52W High
$11.255
52W Position info
8.7% above low
Off High info
28% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

JYNT is trading near its 52-week low of $7.5 (8.7% above the low).

Summary

JOINT Corp beat Q2 revenue estimates, swung to a first-half profit, and reiterated guidance. Refranchising is reducing costs, and the company is buying back stock.


Key Events · Earnings and Guidance · JYNT

  • Q2 Revenue Beat

    Revenue of $15.2 million exceeded the $14.57 million consensus, driven by higher royalty and advertising fees.

  • Swung to H1 Profit

    Continuing operations generated $0.5 million in net income for H1 2026, compared to a $1.8 million loss in H1 2025, as refranchising reduced corporate clinic costs.

  • Guidance Reiterated

    Management reaffirmed its full-year 2026 outlook despite a 2.8% decline in comparable same-store sales.

  • Refranchising Progress

    Sold 29 company-owned clinics in Q2 and entered an agreement to sell 45 Southern California clinics for $2.3 million, advancing the strategy to become an asset-light franchisor.


Analysis · JYNT · Real Estate & Construction

JOINT Corp delivered Q2 revenue of $15.2 million, topping the $14.57 million consensus, and earned $0.05 per share. The franchise-focused business swung to a $0.5 million profit from continuing operations in the first half of 2026, reversing a $1.8 million loss a year ago, as refranchising efforts reduced corporate clinic overhead. Same-store sales fell 2.8%, but the company reiterated its full-year outlook. The balance sheet remains debt-free with $22.2 million in cash, and the board continues to buy back stock — $1.8 million repurchased in the first half. The refranchising of company-owned clinics is progressing, with 29 clinics sold in Q2 and a large Southern California deal in the works, which should further streamline operations.

At the time of this filing, JYNT was trading at $8.15 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $117.2M. The 52-week trading range was $7.50 to $11.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

JYNT - Latest Insights

JYNT
Aug 06, 2026, 4:52 PM EDT
Source: Reuters
Importance Score:
7
JYNT
May 14, 2026, 6:00 PM EDT
Filing Type: 4
Importance Score:
7
JYNT
May 07, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
JYNT
May 01, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
JYNT
Apr 24, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
8